The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable
in vitro
activity against chronic lymphocytic leukemia B cells with CD20 antibodies
The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable
in vitro
activity against chronic lymphocytic leukemia B cells with CD20 antibodies
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now